The New 2016 WSAVA Vaccination Guidelines has Now Been Published.
Within these guidelines, for the first time, there are very specific and detailed descriptions of the essential indications of In Practice Serological Testing, eluding to VacciCheck.
It is now very clear when, how and why it is essential to implement core vaccine titer testing.
Below are some of the mentions of the use of In Practice Serological Testing, such as VacciCheck, within the Guidelines:
Editorial by Professor Ford:
“The guidelines also include new, important information on the role of serological testing for the purpose of assessing vaccine associated immunity among individual patients. With improved point-of-care testing technology, as well as increasing concerns among pet owners over risks associated with excessive vaccination, the opportunity to monitor antibody responses to vaccination at the time of appointment represents a relevant application for clinical practice.”
CLICK HERE to read the full editorial.
GUIDELINES FOR THE VACCINATION OF DOGS AND CATS (M. J. Day, M. C. Horzinek, R. D. Schultz and R. A. Squires):
CLICK HERE to read the full guidelines.
DOGS: “Since publication of the 2010 guidelines there have been advances in the availability of rapid and simple in-practice serological test kits that can detect the presence of protective antibody specific for CDV, CAV and CPV-2 in individual dogs. These test kits complement the traditional laboratory-based modalities (i.e. virus neutralization and haemagglutination inhibition test) that remain the ‘gold standards’ for serological testing. Two commercially produced test kits are available and have been applied and validated in the practice and shelter setting (Gray et al. 2012, Litster et al. 2012) [EB1]. These test kits have proven popular with veterinarians who wish to be able to offer their clients an alternative to routine core revaccination at 3-yearly intervals,”
CATS: “Since the publication of the 2010 guidelines, one commercial in-practice rapid test for determination of serum antibody to FPV, FCV and FHV-1 has become available. This test has now been validated and applied in a series of published investigations (DiGangi et al. 2011, Mende et al. 2014) [EB1]. This test kit may be used for the determination of the presence of protective antibody against FPV as there is excellent correlation between the presence of such antibody and resistance to infection (Lappin et al. 2002) [EB1]. The FPV test kit is reported to have 89% specificity and 79% sensitivity (Mende et al. 2014) or 99% specificity and 49% sensitivity (DiGangi et al. 2011) when compared with a haemagglutination inhibition test. A negative test result indicates that a cat has little or no antibody, and that revaccination is recommended. However, some seronegative cats are in fact immune (false-negative) and their revaccination would be unnecessary. In contrast, a positive test result would lead to the conclusion that revaccination is not required.”
- Can we test dogs as an alternative to annual vaccination? We are concerned about the advice to only boost every 3 years.
Yes, certainly. There are now well-validated in-practice serological test kits that permit determination of the presence of protective serum antibody specific for CDV, CAV, CPV-2 and FPV. In other countries, these kits are used to confirm protection at 3-yearly intervals (instead of automatic revaccination for core diseases). You could perform serology annually, but if you were to collect and analyze the data that you generated within your practice, you will quickly find that annual testing is unjustified.